MicroRNA-219 (miR-219)

MicroRNA-219 (miR-219) is a brain-enriched non-coding RNA that serves as a master regulator of oligodendrocyte maturation and myelination in the central nervous system. It functions by binding to the 3'-untranslated regions (3'-UTRs) of specific target mRNAs, such as Sox6, Hes5, and CaMKIIγ, thereby inducing translational repression or mRNA degradation to coordinate complex developmental and signaling pathways [1.1.1, 1.1.3]. Beyond its role in myelination, miR-219 is involved in modulating NMDA receptor signaling, synaptic plasticity, and the circadian clock, making it a critical factor in maintaining neuronal health and cognitive function [1.1.1, 1.2.1]. In clinical contexts, miR-219 is frequently downregulated in neurological disorders like multiple sclerosis, where its absence contributes to remyelination failure, and in psychiatric conditions such as schizophrenia, where it is linked to glutamatergic dysfunction [1.1.3, 1.2.1]. Furthermore, miR-219 acts as a tumor suppressor in various malignancies, including glioma and hepatocellular carcinoma, by inhibiting cell proliferation and invasion [1.2.1, 1.2.2]. Therapeutic development focuses on miR-219 mimics to promote tissue repair or suppress tumors, and antagomirs to modulate specific signaling pathways, though successful clinical application requires overcoming significant hurdles related to targeted delivery and off-target toxicity [1.1.4, 1.3.4].

Other names

miR-219amiR-219bMIR219hsa-miR-219MicroRNA 219

MicroRNA-219 regulates gene expression post-transcriptionally by binding to the 3'-untranslated region (3'-UTR) of target mRNAs, leading to translational repression or mRNA degradation. Key targets include Sox6, Hes5, and Zfp238 for myelination, and CaMKIIγ for NMDA receptor signaling.